GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: June 25, 2003, 14:20:41 ; Search time 33.3 Seconds
(without alignments)
444.169 Million cell updates/sec

Title: US-09-622-613B-26
Perfect score: 606
Sequence: 1 MSNWATFQQKHIINTPIICN.....ICVKCENQYPVHFAGIGRCP 111

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 908470 seqs, 133250620 residues

Total number of hits satisfying chosen parameters: 908470

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_101002:*
1: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1980.DAT:*
2: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1981.DAT:*
3: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1982.DAT:*
4: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1983.DAT:*
5: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1984.DAT:*
6: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1985.DAT:*
7: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1986.DAT:*
8: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1987.DAT:*
9: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1988.DAT:*
10: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1989.DAT:*
11: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1990.DAT:*
12: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1991.DAT:*
13: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1992.DAT:*
14: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1993.DAT:*
15: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1994.DAT:*
16: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1995.DAT:*
17: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1996.DAT:*
18: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1997.DAT:*
19: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1998.DAT:*
20: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1999.DAT:*
21: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA2000.DAT:*
22: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA2001.DAT:*
23: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA2002.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	606	100.0	111	20	AAY28878	Recombinant Met(-1
2	602	99.3	111	20	AAY28873	Recombinant Met(-1
3	601	99.2	110	20	AAY28877	Recombinant RaCOR1
4	597	98.5	110	20	AAY28872	Rana catesbeiana o
5	596	98.3	111	20	AAY28876	Recombinant Met(-1
6	591	97.5	110	20	AAY28874	Recombinant RaCOR1
7	586.5	96.8	111	20	AAY33321	Frog lectin protei
8	285.5	47.1	105	20	AAY28871	Recombinant Met(-1
9	282.5	46.6	104	18	AAW06544	Antitumour protein
10	281.5	46.5	105	20	AAY28867	Recombinant Met(-1
11	281.5	46.5	112	18	AAW35118	R. pipiens recombi
12	281.5	46.5	251	18	AAW35134	R. pipiens recombi
13	281.5	46.5	254	18	AAW35135	R. pipiens recombi
14	281.5	46.5	355	18	AAW35129	R. pipiens recombi
15	281.5	46.5	355	18	AAW35133	R. pipiens recombi
16	281.5	46.5	366	18	AAW35132	R. pipiens recombi
17	280.5	46.3	104	20	AAY28870	Recombinant RaPLR1
18	278.5	46.0	105	20	AAY28869	Recombinant Met(-1
19	277.5	45.8	105	18	AAW35123	R. pipiens recombi
20	277.5	45.8	105	20	AAY39400	Recombinant frog O
21	277.5	45.8	355	18	AAW35125	R. pipiens recombi
22	277.5	45.8	358	18	AAW35130	R. pipiens recombi
23	276.5	45.6	104	20	AAY28865	Rana pipiens liver
24	276.5	45.6	105	18	AAW35116	R. pipiens recombi
25	276.5	45.6	127	20	AAY28879	Rana pipiens Clone
26	273.5	45.1	104	20	AAY28866	Recombinant RaPLR1
27	272.5	45.0	104	12	AAR12344	Protein with activ
28	272.5	45.0	104	15	AAR47303	ONCONASE (pharmace
29	272.5	45.0	104	17	AAW00736	Protein derived fr
30	272.5	45.0	104	18	AAW30301	Recombinant onc pr
31	272.5	45.0	104	18	AAW06543	Antitumour protein
32	272.5	45.0	104	18	AAW14065	Onconase (RTM) pro
33	272.5	45.0	104	20	AAY33322	Frog onconase prot
34	272.5	45.0	104	20	AAW88233	Rana pipiens RNase
35	272.5	45.0	104	22	AAB31666	Amino acid sequenc
36	272.5	45.0	106	18	AAW35122	R. pipiens recombi
37	272.5	45.0	107	18	AAW35117	R. pipiens recombi
38	272.5	45.0	358	18	AAW35127	R. pipiens recombi
39	272.5	45.0	365	18	AAW35131	R. pipiens recombi
40	272.5	45.0	379	18	AAW35126	R. pipiens recombi
41	270.5	44.6	105	18	AAW35115	R. pipiens recombi
42	269.5	44.5	104	18	AAW30302	Recombinant onc pr
43	267.5	44.1	104	22	AAB31667	Amino acid sequenc
44	265.5	43.8	104	18	AAW18224	Antitumour generic
45	254.5	42.0	107	18	AAW35120	R. pipiens recombi

ALIGNMENTS

RESULT 1
AAY28878
ID AAY28878 standard; Protein; 111 AA.
XX
AC AAY28878;
XX
DT 25-JAN-2000 (first entry)
XX
DE Recombinant Met(-1) RaCOR1 Gln1Ser amino acid sequence.
XX
KW Recombinant Met(-1) Rana catesbeiana oocyte ribonuclease Gln1Ser; RaCOR1;
KW covalently bound; LL2 antibody; ligand binding moiety; cancerous B cell;
KW Kaposi's sarcoma; human chorionic gonadotrophin; hCG; signal peptide;
KW recombinant ribonuclease; cytotoxic fusion protein; cancer; bullfrog;
KW CD22; RNase; autoimmune disease.
XX
OS Rana catesbeiana.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Misc-difference 1
FT /note= "Met not found in wild type RaCOR1"
FT Misc-difference 2
FT /note= "Wild type Gln replaced with Ser"
XX
PN WO9950398-A2.
XX
PD 07-OCT-1999.
XX
PF 26-MAR-1999; 99WO-US06641.
XX
PR 27-MAR-1998; 98US-0079751.
XX

```
PA   (USSH ) US DEPT HEALTH & HUMAN SERVICES.
XX
PI   Newton DL,  Rybak SM;
XX
DR   WPI; 1999-610847/52.
DR   N-PSDB; AAZ08135.
XX
PT   New recombinant ribonucleases, used for killing target cells, e.g. for
PT   treating cancers, viral infections or autoimmune diseases -
XX
PS   Claim 22; Page 68; 71pp; English.
XX
CC   The present sequence is a recombinant Rana catesbeiana ribonuclease
CC   (RaCOR1) protein with Met at position 1 and Gln2Ser. Carboxy terminal end
CC   of recombinant RaCOR1 has a covalently bound ligand binding moiety, which
CC   can be a LL2 antibody directed against CD22 on cancerous B cells or human
CC   chorionic gonadotrophin (hCG) effective against Kaposi's sarcoma cells.
CC   Recombinant ribonucleases can be expressed in bacteria without an N-
CC   terminal methionine due to the presence of a signal peptide that is
CC   cleaved by bacteria. The soluble expression of ribonuclease allows the
CC   proteins to be fused in-frame with ligand binding moieties to form
CC   cytotoxic fusion proteins. They can be used for treatment of cancer and
CC   autoimmune diseases.
XX
SQ   Sequence  111 AA;

  Query Match             100.0%;  Score 606;  DB 20;  Length 111;
  Best Local Similarity   100.0%;  Pred. No. 8e-62;
  Matches  111;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MSNWATFQQKHIINTPIICNTIMDNNIYIVGGQCKRVNTFIISSATTVKAICTGVINMNV 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MSNWATFQQKHIINTPIICNTIMDNNIYIVGGQCKRVNTFIISSATTVKAICTGVINMNV 60

Qy         61 LSTTRFQLNTCTRTSITPRPCPYSSRTETNYICVKCENQYPVHFAGIGRCP 111
              |||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 LSTTRFQLNTCTRTSITPRPCPYSSRTETNYICVKCENQYPVHFAGIGRCP 111


RESULT 2
AAY28873
ID   AAY28873 standard; Protein; 111 AA.
XX
AC   AAY28873;
XX
DT   25-JAN-2000  (first entry)
XX
DE   Recombinant Met(-1) RaCOR1.
XX
KW   Recombinant Met(-1) Rana catesbeiana oocyte ribonuclease; RaCOR1; CD22;
KW   covalently bound; LL2 antibody; ligand binding moiety; cancerous B cell;
KW   Kaposi's sarcoma; human chorionic gonadotrophin; hCG; signal peptide;
KW   recombinant ribonuclease; cytotoxic fusion protein; cancer; bullfrog;
KW   RNase; autoimmune disease.
XX
OS   Rana catesbeiana.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   Misc-difference 1
FT                   /note= "Met not found in wild type RaCOR1"
XX
PN   WO9950398-A2.
XX
PD   07-OCT-1999.
XX
PF   26-MAR-1999;   99WO-US06641.
XX
PR   27-MAR-1998;   98US-0079751.
XX
PA   (USSH ) US DEPT HEALTH & HUMAN SERVICES.
XX
PI   Newton DL,  Rybak SM;
XX
DR   WPI; 1999-610847/52.
DR   N-PSDB; AAZ08131.
XX
PT   New recombinant ribonucleases, used for killing target cells, e.g. for
PT   treating cancers, viral infections or autoimmune diseases -
XX
PS   Claim 22; Page 63; 71pp; English.
XX
CC   The present sequence is a recombinant Rana catesbeiana oocyte
CC   ribonuclease (RaCOR1) protein with Met at position 1. Carboxy terminal
CC   end of recombinant RaCOR1 has a covalently bound ligand binding moiety,
CC   which can be a LL2 antibody directed against CD22 on cancerous B cells or
CC   human chorionic gonadotrophin (hCG) effective against Kaposi's sarcoma
CC   cells. Recombinant ribonucleases can be expressed in bacteria without an
CC   N-terminal methionine due to the presence of a signal peptide that is
CC   cleaved by bacteria. The soluble expression of ribonuclease allows the
CC   proteins to be fused in-frame with ligand binding moieties to form
CC   cytotoxic fusion proteins. They can be used for treatment of cancer and
CC   autoimmune diseases.
XX
SQ   Sequence  111 AA;

  Query Match             99.3%;  Score 602;  DB 20;  Length 111;
  Best Local Similarity   99.1%;  Pred. No. 2.3e-61;
  Matches  110;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          1 MSNWATFQQKHIINTPIICNTIMDNNIYIVGGQCKRVNTFIISSATTVKAICTGVINMNV 60
              | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MQNWATFQQKHIINTPIICNTIMDNNIYIVGGQCKRVNTFIISSATTVKAICTGVINMNV 60

Qy         61 LSTTRFQLNTCTRTSITPRPCPYSSRTETNYICVKCENQYPVHFAGIGRCP 111
              |||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 LSTTRFQLNTCTRTSITPRPCPYSSRTETNYICVKCENQYPVHFAGIGRCP 111


RESULT 3
AAY28877
ID   AAY28877 standard; Protein; 110 AA.
XX
AC   AAY28877;
XX
DT   25-JAN-2000  (first entry)
XX
DE   Recombinant RaCOR1 Gln1Ser amino acid sequence.
XX
KW   Recombinant Rana catesbeiana oocyte ribonuclease; RaCOR1 Gln1Ser; CD22;
KW   covalently bound; LL2 antibody; ligand binding moiety; cancerous B cell;
KW   bullfrog; Kaposi's sarcoma; human chorionic gonadotrophin; hCG; RNase;
KW   signal peptide; recombinant ribonuclease; cytotoxic fusion protein;
KW   cancer; autoimmune disease.
XX
OS   Rana catesbeiana.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   Misc-difference 1
FT                   /note= "Wild type Gln replaced with Ser"
XX
PN   WO9950398-A2.
XX
PD   07-OCT-1999.
XX
PF   26-MAR-1999;   99WO-US06641.
XX
PR   27-MAR-1998;   98US-0079751.
XX
PA   (USSH ) US DEPT HEALTH & HUMAN SERVICES.
XX
PI   Newton DL,  Rybak SM;
XX
DR   WPI; 1999-610847/52.
DR   N-PSDB; AAZ08134.
```

```
XX
PT   New recombinant ribonucleases, used for killing target cells, e.g. for
PT   treating cancers, viral infections or autoimmune diseases -
XX
PS   Claim 22; Page 67; 71pp; English.
XX
CC   The present sequence is a recombinant Rana catesbeiana oocyte
CC   ribonuclease (RaCOR1) protein with Gln1Ser. Carboxy terminal end of
CC   recombinant RaCOR1 has a covalently bound ligand binding moiety, which
CC   can be a LL2 antibody directed against CD22 on cancerous B cells or
CC   human chorionic gonadotrophin (hCG) effective against Kaposi's sarcoma
CC   cells. Recombinant ribonucleases can be expressed in bacteria without an
CC   N-terminal methionine due to the presence of a signal peptide that is
CC   cleaved by bacteria. The soluble expression of ribonuclease allows the
CC   proteins to be fused in-frame with ligand binding moieties to form
CC   cytotoxic fusion proteins. They can be used for treatment of cancer and
CC   autoimmune diseases.
XX
SQ   Sequence   110 AA;

  Query Match           99.2%;  Score 601;  DB 20;  Length 110;
  Best Local Similarity  100.0%;  Pred. No. 3e-61;
  Matches  110;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          2 SNWATFQQKHIINTPIICNTIMDNNIYIVGGQCKRVNTFIISSATTVKAICTGVINMNVL 61
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 SNWATFQQKHIINTPIICNTIMDNNIYIVGGQCKRVNTFIISSATTVKAICTGVINMNVL 60

Qy         62 STTRFQLNTCTRTSITPRPCPYSSRTETNYICVKCENQYPVHFAGIGRCP 111
              |||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 STTRFQLNTCTRTSITPRPCPYSSRTETNYICVKCENQYPVHFAGIGRCP 110


RESULT 4
AAY28872
ID   AAY28872 standard; Protein; 110 AA.
XX
AC   AAY28872;
XX
DT   25-JAN-2000  (first entry)
XX
DE   Rana catesbeiana oocyte ribonuclease (RaCOR1) amino acid sequence.
XX
KW   Rana catesbeiana oocyte ribonuclease; RaCOR1; covalently bound; CD22;
KW   LL2 antibody; ligand binding moiety; cancerous B cell; Kaposi's Sarcoma;
KW   human chorionic gonadotrophin; hCG; recombinant ribonuclease; bullfrog;
KW   signal peptide; cytotoxic fusion protein; cancer; autoimmune disease;
KW   RNase.
XX
OS   Rana catesbeiana.
OS   Synthetic.
XX
PN   WO9950398-A2.
XX
PD   07-OCT-1999.
XX
PF   26-MAR-1999;   99WO-US06641.
XX
PR   27-MAR-1998;   98US-0079751.
XX
PA   (USSH ) US DEPT HEALTH & HUMAN SERVICES.
XX
PI   Newton DL,  Rybak SM;
XX
DR   WPI; 1999-610847/52.
DR   N-PSDB; AAZ08130.
XX
PT   New recombinant ribonucleases, used for killing target cells, e.g. for
PT   treating cancers, viral infections or autoimmune diseases -
XX
PS   Claim 22; Page 62; 71pp; English.
XX
CC   The present sequence is a Rana catesbeiana oocyte ribonuclease (RaCOR1)
CC   protein encoded by a cDNA modified for expression in E. coli. Carboxy
CC   terminal end of RaCOR1 has a covalently bound ligand binding moiety,
CC   which can be a LL2 antibody directed against CD22 on cancerous B cells
CC   or human chorionic gonadotrophin (hCG) effective against Kaposi's
CC   Sarcoma cells. Recombinant ribonucleases can be expressed in bacteria
CC   without an N-terminal methionine due to the presence of a signal peptide
CC   that is cleaved by bacteria. The soluble expression of ribonuclease
CC   allows the proteins to be fused in-frame with ligand binding moieties to
CC   form cytotoxic fusion proteins. They can be used for treatment of cancer
CC   and autoimmune diseases.
XX
SQ   Sequence   110 AA;

  Query Match           98.5%;  Score 597;  DB 20;  Length 110;
  Best Local Similarity  100.0%;  Pred. No. 8.5e-61;
  Matches  109;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          3 NWATFQQKHIINTPIICNTIMDNNIYIVGGQCKRVNTFIISSATTVKAICTGVINMNVLS 62
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          2 NWATFQQKHIINTPIICNTIMDNNIYIVGGQCKRVNTFIISSATTVKAICTGVINMNVLS 61

Qy         63 TTRFQLNTCTRTSITPRPCPYSSRTETNYICVKCENQYPVHFAGIGRCP 111
              |||||||||||||||||||||||||||||||||||||||||||||||||
Db         62 TTRFQLNTCTRTSITPRPCPYSSRTETNYICVKCENQYPVHFAGIGRCP 110


RESULT 5
AAY28876
ID   AAY28876 standard; Protein; 111 AA.
XX
AC   AAY28876;
XX
DT   25-JAN-2000  (first entry)
XX
DE   Recombinant Met(-1) RaCOR1 Met22Leu Met57Leu-(His)6 protein.
XX
KW   Met(-1) Rana catesbeiana ribonuclease Met22Leu Met57Leu-(His)6; RaCOR1;
KW   recombinant; CD22; covalently bound; LL2 antibody; ligand binding moiety;
KW   cancerous B cell; Kaposi's sarcoma; human chorionic gonadotrophin; hCG;
KW   signal peptide; recombinant ribonuclease; cytotoxic fusion protein;
KW   cancer; bullfrog; RNase; autoimmune disease.
XX
OS   Rana catesbeiana.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   Misc-difference 1
FT                   /note= "(His)6 histidine tag attached to N-terminal Met"
FT   Misc-difference 1
FT                   /note= "Met not found in wild type RaCOR1"
FT   Misc-difference 23
FT                   /note= "Wild type Met replaced with Leu"
FT   Misc-difference 58
FT                   /note= "Wild type Met replaced with Leu"
XX
PN   WO9950398-A2.
XX
PD   07-OCT-1999.
XX
PF   26-MAR-1999;   99WO-US06641.
XX
PR   27-MAR-1998;   98US-0079751.
XX
PA   (USSH ) US DEPT HEALTH & HUMAN SERVICES.
XX
PI   Newton DL,  Rybak SM;
XX
DR   WPI; 1999-610847/52.
DR   N-PSDB; AAZ08133.
XX
PT   New recombinant ribonucleases, used for killing target cells, e.g. for
PT   treating cancers, viral infections or autoimmune diseases -
XX
```

```
PS   Claim 22; Page 66; 71pp; English.
XX
CC   The present sequence is a recombinant Rana catesbeiana oocyte
CC   ribonuclease (RaCOR1) protein with Met at position 1 attached to a
CC   (His)6 tag, Met23Leu and Met58Leu. Carboxy terminal end of recombinant
CC   RaCOR1 has a covalently bound ligand binding moiety, which can be a LL2
CC   antibody directed against CD22 on cancerous B cells or human chorionic
CC   gonadotrophin (hCG) effective against Kaposi's sarcoma cells. Recombinant
CC   ribonucleases can be expressed in bacteria without an N-terminal
CC   methionine due to the presence of a signal peptide that is cleaved by
CC   bacteria. The soluble expression of ribonuclease allows the proteins to
CC   be fused in-frame with ligand binding moieties to form cytotoxic fusion
CC   proteins. They can be used for treatment of cancer and autoimmune
CC   diseases.
XX
SQ   Sequence   111 AA;

  Query Match             98.3%;  Score 596;  DB 20;  Length 111;
  Best Local Similarity   97.3%;  Pred. No. 1.1e-60;
  Matches  108;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          1 MSNWATFQQKHIINTPIICNTIMDNNIYIVGGQCKRVNTFIISSATTVKAICTGVINMNV 60
              | ||||||||||||||||||:|||||||||||||||||||||||||||||||:||
Db          1 MQNWATFQQKHIINTPIICNTILDNNIYIVGGQCKRVNTFIISSATTVKAICTGVINLNV 60

Qy         61 LSTTRFQLNTCTRTSITPRPCPYSSRTETNYICVKCENQYPVHFAGIGRCP 111
              ||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 LSTTRFQLNTCTRTSITPRPCPYSSRTETNYICVKCENQYPVHFAGIGRCP 111


RESULT 6
AAY28874
ID   AAY28874 standard; Protein; 110 AA.
XX
AC   AAY28874;
XX
DT   25-JAN-2000  (first entry)
XX
DE   Recombinant RaCOR1 Met22Leu Met57Leu amino acid sequence.
XX
KW   Recombinant Rana catesbeiana oocyte ribonuclease; covalently bound;
KW   RaCOR1 Met22Leu Met57Leu; LL2 antibody; ligand binding moiety; CD22;
KW   cancerous B cell; Kaposi's sarcoma; human chorionic gonadotrophin; hCG;
KW   signal peptide; recombinant ribonuclease; cytotoxic fusion protein;
KW   cancer; bullfrog; RNase; autoimmune disease.
XX
OS   Rana catesbeiana.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   Misc-difference 22
FT                   /note= "Wild type Met replaced with Leu"
FT   Misc-difference 57
FT                   /note= "Wild type Met replaced with Leu"
XX
PN   WO9950398-A2.
XX
PD   07-OCT-1999.
XX
PF   26-MAR-1999;   99WO-US06641.
XX
PR   27-MAR-1998;   98US-0079751.
XX
PA   (USSH ) US DEPT HEALTH & HUMAN SERVICES.
XX
PI   Newton DL,  Rybak SM;
XX
DR   WPI; 1999-610847/52.
DR   N-PSDB; AAZ08132.
XX
PT   New recombinant ribonucleases, used for killing target cells, e.g. for
PT   treating cancers, viral infections or autoimmune diseases  -
XX
```

```
PS   Claim 22; Page 64; 71pp; English.
XX
CC   The present sequence is a recombinant Rana catesbeiana oocyte
CC   ribonuclease (RaCOR1) protein with Met22Leu Met57Leu. Carboxy terminal
CC   end of recombinant RaCOR1 has a covalently bound ligand binding moiety,
CC   which can be a LL2 antibody directed against CD22 on cancerous B cells
CC   or human chorionic gonadotrophin (hCG) effective against Kaposi's sarcoma
CC   cells. Recombinant ribonucleases can be expressed in bacteria without an
CC   N-terminal methionine due to the presence of a signal peptide that is
CC   cleaved by bacteria. The soluble expression of ribonuclease allows the
CC   proteins to be fused in-frame with ligand binding moieties to form
CC   cytotoxic fusion proteins. They can be used for treatment of cancer and
CC   autoimmune diseases.
XX
SQ   Sequence   110 AA;

  Query Match             97.5%;  Score 591;  DB 20;  Length 110;
  Best Local Similarity   98.2%;  Pred. No. 4.2e-60;
  Matches  107;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          3 NWATFQQKHIINTPIICNTIMDNNIYIVGGQCKRVNTFIISSATTVKAICTGVINMNVLS 62
              ||||||||||||||||||:||||||||||||||||||||||||||||||:||||
Db          2 NWATFQQKHIINTPIICNTILDNNIYIVGGQCKRVNTFIISSATTVKAICTGVINLNVLS 61

Qy         63 TTRFQLNTCTRTSITPRPCPYSSRTETNYICVKCENQYPVHFAGIGRCP 111
              ||||||||||||||||||||||||||||||||||||||||||||||||||
Db         62 TTRFQLNTCTRTSITPRPCPYSSRTETNYICVKCENQYPVHFAGIGRCP 110


RESULT 7
AAY33321
ID   AAY33321 standard; Protein; 111 AA.
XX
AC   AAY33321;
XX
DT   29-NOV-1999  (first entry)
XX
DE   Frog lectin protein fragment.
XX
KW   Cytotoxic; RNase; ribonuclease; pancreatic; antibody; light chain;
KW   heavy chain; cell surface marker; treatment; tumor; viral infection;
KW   parasite infection; immune dysfunctional cell; autoimmune disease;
KW   contraceptive; cell separation; transplantation; bone marrow ablation;
KW   leukemia cell; T-cell; graft-versus-host disease; bullfrog; lectin.
XX
OS   Rana catesbeiana.
XX
PN   US5955073-A.
XX
PD   21-SEP-1999.
XX
PF   09-JUL-1997;   97US-0891848.
XX
PR   22-SEP-1993;   93US-0125462.
PR   22-OCT-1991;   91US-0779195.
PR   20-APR-1990;   90US-0510696.
PR   04-FEB-1993;   93US-0014082.
XX
PA   (USSH ) US DEPT HEALTH & HUMAN SERVICES.
XX
PI   Rybak SM,  Newton DL,  Nicholls PJ,  Youle RJ;
XX
DR   WPI; 1999-560488/47.
XX
PT   Recombinantly fused pancreatic RNase-targeting proteins useful for
PT   treating tumors, infections, immune or autoimmune disorders and as a
PT   contraceptive -
XX
PS   Example 3; Fig 19; 47pp; English.
XX
CC   This invention describes a novel nucleic acid construct comprising
CC   sequences encoding functional pancreatic RNase and a second protein
CC   (preferably the light and heavy chains of an antibody) which binds a
```

```
CC   specific cell surface marker on a target cell and functions as a
CC   cytotoxic agent. The products can be used for selectively killing cells
CC   expressing a specific surface marker. They can be used for treating
CC   tumors or infected cells (e.g. cells infected by viruses (especially
CC   latent or chronic virus infections, such as human immunodeficiency virus
CC   (HIV)-1, Epstein-Barr virus, herpes viruses (herpes simplex types I and
CC   II), hepatitis viruses (B, non-A-non-B, and delta), herpes zoster,
CC   cytomegalovirus)) and cells infected with parasites (such as the malaria
CC   parasite)). They can also be used for treating immune dysfunctional cells
CC   in immune and autoimmune diseases. Additionally, they may be used as
CC   contraceptives. Finally they can also be used for cell separation in
CC   vitro by selectively killing unwanted types of cells (e.g. in bone
CC   marrow) prior to transplantation into a patient undergoing marrow
CC   ablation by radiation or for killing leukemia cells or T-cells that would
CC   cause graft-versus-host disease. This sequence represents a bullfrog
CC   (Rana catesbeiana) lectin used to describe the method of the invention.
XX
SQ   Sequence  111 AA;

  Query Match           96.8%;  Score 586.5;  DB 20;  Length 111;
  Best Local Similarity  99.1%;  Pred. No. 1.4e-59;
  Matches  109;  Conservative    0;  Mismatches    0;  Indels    1;  Gaps    1;

Qy          3 NWATFQQKHIINTPII-CNTIMDNNIYIVGGQCKRVNTFIISSATTVKAICTGVINMNVL 61
              |||||||||||||||| ||||||||||||||||||||||||||||||||||||||||||
Db          2 NWATFQQKHIINTPIINCNTIMDNNIYIVGGQCKRVNTFIISSATTVKAICTGVINMNVL 61

Qy         62 STTRFQLNTCTRTSITPRPCPYSSRTETNYICVKCENQYPVHFAGIGRCP 111
              ||||||||||||||||||||||||||||||||||||||||||||||||||
Db         62 STTRFQLNTCTRTSITPRPCPYSSRTETNYICVKCENQYPVHFAGIGRCP 111


RESULT 8
AAY28871
ID   AAY28871 standard; Protein; 105 AA.
XX
AC   AAY28871;
XX
DT   25-JAN-2000  (first entry)
XX
DE   Recombinant Met(-1) RaPLR1 Gln1Ser amino acid sequence.
XX
KW   Recombinant Met(-1) Rana pipiens ribonuclease Gln1Ser; RaPLR1; CD22;
KW   covalently bound; LL2 antibody; ligand binding moiety; cancerous B cell;
KW   Kaposi's sarcoma; human chorionic gonadotrophin; hCG; signal peptide;
KW   recombinant ribonuclease; cytotoxic fusion protein; cancer; frog;
KW   autoimmune disease; RNase.
XX
OS   Rana pipiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   Misc-difference  1
FT                   /note= "Met not found in wild type RaPLR1"
FT   Misc-difference  2
FT                   /note= "Wild type Gln replaced with Ser"
XX
PN   WO9950398-A2.
XX
PD   07-OCT-1999.
XX
PF   26-MAR-1999;   99WO-US06641.
XX
PR   27-MAR-1998;   98US-0079751.
XX
PA   (USSH ) US DEPT HEALTH & HUMAN SERVICES.
XX
PI   Newton DL,  Rybak SM;
XX
DR   WPI; 1999-610847/52.
DR   N-PSDB; AAZ08129.
XX
PT   New recombinant ribonucleases, used for killing target cells, e.g. for
PT   treating cancers, viral infections or autoimmune diseases -
XX
PS   Claim 34; Page 61; 71pp; English.
XX
CC   The present sequence is a recombinant Rana pipiens ribonuclease (RaPLR1)
CC   protein with Met at position 1 and Gln2Ser. Carboxy terminal end of
CC   recombinant RaPLR1 has a covalently bound ligand binding moiety, which
CC   can be a LL2 antibody directed against CD22 on cancerous B cells or human
CC   chorionic gonadotrophin (hCG) effective against Kaposi's sarcoma cells.
CC   Recombinant ribonucleases can be expressed in bacteria without an N-
CC   terminal methionine due to the presence of a signal peptide that is
CC   cleaved by bacteria. The soluble expression of ribonuclease allows the
CC   proteins to be fused in-frame with ligand binding moieties to form
CC   cytotoxic fusion proteins. They can be used for treatment of cancer and
CC   autoimmune diseases.
XX
SQ   Sequence  105 AA;

  Query Match           47.1%;  Score 285.5;  DB 20;  Length 105;
  Best Local Similarity  50.0%;  Pred. No. 4.8e-25;
  Matches   56;  Conservative   15;  Mismatches   32;  Indels    9;  Gaps    4;

Qy          1 MSNWATFQQKHIINT-PIICNTIMDNNIYIVGGQCKRVNTFIISSATTVKAICTGVI-NM 58
              ||:| |||:||: ||  : || ||  |::     ||  |||| |    ||||| |:| :
Db          1 MSDWLTFQKKHLTNTRDVDCNNIMSTNLF----HCKDKNTFIYSRPEPVKAICKGIIASK 56

Qy         59 NVLSTTRFQLNTCTRTSITPRPCPYSSRTETNYICVKCENQYPVHFAGIGRC 110
              |||:|: | |: |   ::| ||| |  :  ||  || |||| |||| |:| |
Db         57 NVLTTSEFYLSDC---NVTSRPCKYKLKKSTNTFCVTCENQAPVHFVGVGHC 105


RESULT 9
AAW06544
ID   AAW06544 standard; protein; 104 AA.
XX
AC   AAW06544;
XX
DT   22-AUG-1997  (first entry)
XX
DE   Antitumour protein from Rana pipiens oocytes.
XX
KW   Tumour; chemotherapy; radiotherapy; frog.
XX
OS   Rana pipiens.
XX
PN   WO9639428-A1.
XX
PD   12-DEC-1996.
XX
PF   03-JUN-1996;   96WO-US08304.
XX
PR   06-JUN-1995;   95US-0467955.
XX
PA   (ALFA-) ALFACELL CORP.
XX
PI   Ardelt WJ;
XX
DR   WPI; 1997-043063/04.
XX
PT   Antitumour proteins from Rana pipiens oocyte(s) - have fewer
PT   disadvantages than chemotherapy, surgery and radiotherapy
XX
PS   Claim 8; Page 28; 45pp; English.
XX
CC   The present sequence is a specifically claimed example of an
CC   antitumour protein from the generic protein in AAW18224, with the
CC   molecular weight 12000. This is one of two preferred proteins (the
CC   other in AAW06543) that have been isolated from Rana pipiens oocytes.
CC   Both proteins have a blocked amino terminal group and are essentially
CC   free of carbohydrates. The proteins are used to treat tumours. Use of
CC   the peptides has fewer disadvantages than chemotherapy, radiotherapy
CC   and surgery in the treatment of tumours.
XX
```

```
SQ   Sequence   104 AA;

  Query Match             46.6%;  Score 282.5;  DB 18;  Length 104;
  Best Local Similarity   50.0%;  Pred. No. 1.1e-24;
  Matches   55;  Conservative   15;  Mismatches   31;  Indels    9;  Gaps    4;

Qy          3 NWATFQQKHIINT-PIICNTIMDNNIYIVGGQCKRVNTFIISSATTVKAICTGVI-NMNV 60
              :| |||:||: ||  : || ||  |::     ||  |||| |    ||||| |:| : ||
Db          2 DWLTFQKKHVTNTRDVDCNNIMSTNLF----HCKDKNTFIYSRPEPVKAICKGIIASKNV 57

Qy         61 LSTTRFQLNTCTRTSITPRPCPYSSRTETNYICVKCENQYPVHFAGIGRC 110
              |:|: | |: |   ::| ||| |  :  ||  || |||| |||| |:|||
Db         58 LTTSEFYLSDC---NVTSRPCKYKLKKSTNKFCVTCENQAPVHFVGVGRC 104


RESULT 10
AAY28867
ID   AAY28867 standard; Protein; 105 AA.
XX
AC   AAY28867;
XX
DT   25-JAN-2000  (first entry)
XX
DE   Recombinant Met(-1) RaPLR1.
XX
KW   Recombinant Met(-1) Rana pipiens ribonuclease; RaPLR1; CD22; RNase;
KW   covalently bound; LL2 antibody; ligand binding moiety; cancerous B cell;
KW   Kaposi's sarcoma; human chorionic gonadotrophin; hCG; signal peptide;
KW   recombinant ribonuclease; cytotoxic fusion protein; cancer; frog;
KW   autoimmune disease.
XX
OS   Rana pipiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   Misc-difference 1
FT                   /note= "Met not found in wild type RaPLR1"
XX
PN   WO9950398-A2.
XX
PD   07-OCT-1999.
XX
PF   26-MAR-1999;   99WO-US06641.
XX
PR   27-MAR-1998;   98US-0079751.
XX
PA   (USSH ) US DEPT HEALTH & HUMAN SERVICES.
XX
PI   Newton DL,  Rybak SM;
XX
DR   WPI; 1999-610847/52.
DR   N-PSDB; AAZ08126.
XX
PT   New recombinant ribonucleases, used for killing target cells, e.g. for
PT   treating cancers, viral infections or autoimmune diseases
XX
PS   Claim 34; Page 57; 71pp; English.
XX
CC   The present sequence is a recombinant Rana pipiens ribonuclease (RaPLR1)
CC   protein with Met at position 1. Carboxy terminal end of recombinant
CC   RaPLR1 has a covalently bound ligand binding moiety, which can be a LL2
CC   antibody directed against CD22 on cancerous B cells or human chorionic
CC   gonadotrophin (hCG) effective against Kaposi's sarcoma cells. Recombinant
CC   ribonucleases can be expressed in bacteria without an N-terminal
CC   methionine due to the presence of a signal peptide that is cleaved by
CC   bacteria. The soluble expression of ribonuclease allows the proteins to
CC   be fused in-frame with ligand binding moieties to form cytotoxic fusion
CC   proteins. They can be used for treatment of cancer and autoimmune
CC   diseases.
XX
SQ   Sequence   105 AA;

  Query Match             46.5%;  Score 281.5;  DB 20;  Length 105;
  Best Local Similarity   49.1%;  Pred. No. 1.4e-24;
  Matches   55;  Conservative   15;  Mismatches   33;  Indels    9;  Gaps    4;

Qy          1 MSNWATFQQKHIINT-PIICNTIMDNNIYIVGGQCKRVNTFIISSATTVKAICTGVI-NM 58
              | :| |||:||: ||  : || ||  |::     ||  |||| |    ||||| |:| :
Db          1 MQDWLTFQKKHLTNTRDVDCNNIMSTNLF----HCKDKNTFIYSRPEPVKAICKGIIASK 56

Qy         59 NVLSTTRFQLNTCTRTSITPRPCPYSSRTETNYICVKCENQYPVHFAGIGRC 110
              |||:|: | |: |   ::| ||| |  :  ||  || |||| |||| |:| |
Db         57 NVLTTSEFYLSDC---NVTSRPCKYKLKKSTNFCVTCENQAPVHFVGVGHC 105


RESULT 11
AAW35118
ID   AAW35118 standard; Protein; 112 AA.
XX
AC   AAW35118;
XX
DT   20-APR-1998  (first entry)
XX
DE   R. pipiens recombinant RNase protein NLSMetSerrOnc.
XX
KW   RNase A; ribonuclease; cytotoxic; onconase; nOnc; immunofusion;
KW   tumour cell growth; frog.
XX
OS   Rana pipiens.
XX
PN   WO9731116-A2.
XX
PD   28-AUG-1997.
XX
PF   19-FEB-1997;   97WO-US02588.
XX
PR   21-FEB-1996;   96US-0011800.
XX
PA   (USSH ) US DEPT HEALTH & HUMAN SERVICES.
XX
PI   Boque L,  Newton DL,  Rybak SM,  Wlodawer A;
XX
DR   WPI; 1997-435168/40.
DR   N-PSDB; AAT94955.
XX
PT   Ribonuclease molecules based on native Onconase - used for killing
PT   cells, particularly tumour cells
XX
PS   Claim 18; Page 63; 90pp; English.
XX
CC   AAW35115 to AAW35123 encode recombinant proteins (rOnc) which are
CC   modifications of the RNase Onconase (RTM) (nOnc). Such novel
CC   ribonuclease molecules are highly cytotoxic and can be used alone or to
CC   form chemical conjugates or to target recombinant immunofusions. They are
CC   used particularly for decreasing tumour cell growth. They can also be
CC   used for cell separation in vitro by selectively killing unwanted types
CC   of cells, e.g. in bone marrow prior to transplantation into a patient
CC   undergoing marrow ablation by radiation, or for killing leukaemia cells
CC   or T-cells that would cause graft versus host disease. The toxins can
CC   also be used to selectively kill unwanted cells in culture. The new
CC   ribonucleases have increased cytotoxic activity compared to nOnc and also
CC   lower immunogenicity in humans.
XX
SQ   Sequence   112 AA;

  Query Match             46.5%;  Score 281.5;  DB 18;  Length 112;
  Best Local Similarity   50.0%;  Pred. No. 1.5e-24;
  Matches   56;  Conservative   15;  Mismatches   32;  Indels    9;  Gaps    4;

Qy          1 MSNWATFQQKHIINT-PIICNTIMDNNIYIVGGQCKRVNTFIISSATTVKAICTGVI-NM 58
              ||:| |||:||| ||  : |: ||  |::     ||  |||| |    ||||| |:| :
Db          8 MSDWLTFQKKHITNTRDVDCDNIMSTNLF----HCKDKNTFIYSRPEPVKAICKGIIASK 63

Qy         59 NVLSTTRFQLNTCTRTSITPRPCPYSSRTETNYICVKCENQYPVHFAGIGRC 110
              |||:|: | |: |   ::| ||| |  :  ||  || |||| |||| |:| |
Db         64 NVLTTSEFYLSDC---NVTSRPCKYKLKKSTNKFCVTCENQAPVHFVGVGSC 112
```

```
RESULT 12
AAW35134
ID   AAW35134 standard; Protein; 251 AA.
XX
AC   AAW35134;
XX
DT   20-APR-1998  (first entry)
XX
DE   R. pipiens recombinant RNase rOnc fusion protein 10.
XX
KW   RNase A; ribonuclease; cytotoxic; onconase; nOnc; immunofusion;
KW   tumour cell growth; frog.
XX
OS   Rana pipiens.
OS   Synthetic.
XX
PN   WO9731116-A2.
XX
PD   28-AUG-1997.
XX
PF   19-FEB-1997;  97WO-US02588.
XX
PR   21-FEB-1996;  96US-0011800.
XX
PA   (USSH ) US DEPT HEALTH & HUMAN SERVICES.
XX
PI   Boque L,  Newton DL,  Rybak SM,  Wlodawer A;
XX
DR   WPI; 1997-435158/40.
DR   N-PSDB; AAT94972.
XX
PT   Ribonuclease molecules based on native Onconase - used for killing
PT   cells, particularly tumour cells
XX
PS   Disclosure; Page 76; 90pp; English.
XX
CC   Sequences AAW35125 to AAW35135 represent recombinant fusion proteins
CC   (rOnc) which are modifications of the RNase Onconase (RTM) (nOnc). Such
CC   novel ribonuclease molecules are highly cytotoxic and can be used alone
CC   or to form chemical conjugates or to target recombinant immunofusions.
CC   They are used particularly for decreasing tumour cell growth. They can
CC   also be used for cell separation in vitro by selectively killing unwanted
CC   types of cells, e.g. in bone marrow prior to transplantation into a
CC   patient undergoing marrow ablation by radiation, or for killing leukaemia
CC   cells or T-cells that would cause graft versus host disease. The toxins
CC   can also be used to selectively kill unwanted cells in culture. The new
CC   ribonucleases have increased cytotoxic activity compared to nOnc and
CC   also lower immunogenicity in humans.
XX
SQ   Sequence   251 AA;

  Query Match           46.5%;  Score 281.5;  DB 18;  Length 251;
  Best Local Similarity  50.0%;  Pred. No. 4.1e-24;
  Matches   56;  Conservative   15;  Mismatches   32;  Indels    9;  Gaps    4;

Qy          1 MSNWATFQQKHIINT-PIICNTIMDNNIYIVGGQCKRVNTFIISSATTVKAICTGVI-NM 58
              ||:| |||:||| || : |: || |::     || |||| |    ||||| |:| :
Db        147 MSDWLTFQKKHITNTRDVDCDNIMSTNLF----HCKDKNTFIYSRPEPVKAICKGIIASK 202

Qy         59 NVLSTTRFQLNTCTRTSITPRPCPYSSRTETNYICVKCENQYPVHFAGIGRC 110
              |||:|: | |: |   ::| ||| |   :  ||  || |||| |||| |:| |
Db        203 NVLTTSEFYLSDC---NVTSRPCKYKLKKSTNKFCVTCENQAPVHFVGVGSC 251


RESULT 13
AAW35135
ID   AAW35135 standard; Protein; 254 AA.
XX
AC   AAW35135;
XX
DT   20-APR-1998  (first entry)
XX
DE   R. pipiens recombinant RNase rOnc fusion protein 11.
XX
KW   RNase A; ribonuclease; cytotoxic; onconase; nOnc; immunofusion;
KW   tumour cell growth; frog.
XX
OS   Rana pipiens.
OS   Synthetic.
XX
PN   WO9731116-A2.
XX
PD   28-AUG-1997.
XX
PF   19-FEB-1997;  97WO-US02588.
XX
PR   21-FEB-1996;  96US-0011800.
XX
PA   (USSH ) US DEPT HEALTH & HUMAN SERVICES.
XX
PI   Boque L,  Newton DL,  Rybak SM,  Wlodawer A;
XX
DR   WPI; 1997-435168/40.
DR   N-PSDB; AAT94973.
XX
PT   Ribonuclease molecules based on native Onconase - used for killing
PT   cells, particularly tumour cells
XX
PS   Disclosure; Page 77; 90pp; English.
XX
CC   Sequences AAW35125 to AAW35135 represent recombinant fusion proteins
CC   (rOnc) which are modifications of the RNase Onconase (RTM) (nOnc). Such
CC   novel ribonuclease molecules are highly cytotoxic and can be used alone
CC   or to form chemical conjugates or to target recombinant immunofusions.
CC   They are used particularly for decreasing tumour cell growth. They can
CC   also be used for cell separation in vitro by selectively killing unwanted
CC   types of cells, e.g. in bone marrow prior to transplantation into a
CC   patient undergoing marrow ablation by radiation, or for killing leukaemia
CC   cells or T-cells that would cause graft versus host disease. The toxins
CC   can also be used to selectively kill unwanted cells in culture. The new
CC   ribonucleases have increased cytotoxic activity compared to nOnc and
CC   also lower immunogenicity in humans.
XX
SQ   Sequence   254 AA;

  Query Match           46.5%;  Score 281.5;  DB 18;  Length 254;
  Best Local Similarity  50.0%;  Pred. No. 4.2e-24;
  Matches   56;  Conservative   15;  Mismatches   32;  Indels    9;  Gaps    4;

Qy          1 MSNWATFQQKHIINT-PIICNTIMDNNIYIVGGQCKRVNTFIISSATTVKAICTGVI-NM 58
              ||:| |||:||| || : |: || |::     || |||| |    ||||| |:| :
Db          1 MSDWLTFQKKHITNTRDVDCDNIMSTNLF----HCKDKNTFIYSRPEPVKAICKGIIASK 56

Qy         59 NVLSTTRFQLNTCTRTSITPRPCPYSSRTETNYICVKCENQYPVHFAGIGRC 110
              |||:|: | |: |   ::| ||| |   :  ||  || |||| |||| |:| |
Db         57 NVLTTSEFYLSDC---NVTSRPCKYKLKKSTNKFCVTCENQAPVHFVGVGSC 105


RESULT 14
AAW35129
ID   AAW35129 standard; Protein; 355 AA.
XX
AC   AAW35129;
XX
DT   20-APR-1998  (first entry)
XX
DE   R. pipiens recombinant RNase rOnc fusion protein 5.
XX
KW   RNase A; ribonuclease; cytotoxic; onconase; nOnc; immunofusion;
KW   tumour cell growth; frog.
XX
OS   Rana pipiens.
OS   Synthetic.
XX
```

```
PN   WO9731116-A2.
XX
PD   28-AUG-1997.
XX
PF   19-FEB-1997;   97WO-US02588.
XX
PR   21-FEB-1996;   96US-0011800.
XX
PA   (USSH ) US DEPT HEALTH & HUMAN SERVICES.
XX
PI   Boque L,  Newton DL,  Rybak SM,  Wlodawer A;
XX
DR   WPI; 1997-435168/40.
DR   N-PSDB; AAT94967.
XX
PT   Ribonuclease molecules based on native Onconase - used for killing
PT   cells, particularly tumour cells
XX
PS   Disclosure; Page 71; 90pp; English.
XX
CC   Sequences AAW35125 to AAW35135 represent recombinant fusion proteins
CC   (rOnc) which are modifications of the RNase Onconase (RTM) (nOnc). Such
CC   novel ribonuclease molecules are highly cytotoxic and can be used alone
CC   or to form chemical conjugates or to target recombinant immunofusions.
CC   They are used particularly for decreasing tumour cell growth. They can
CC   also be used for cell separation in vitro by selectively killing unwanted
CC   types of cells, e.g. in bone marrow prior to transplantation into a
CC   patient undergoing marrow ablation by radiation, or for killing leukaemia
CC   cells or T-cells that would cause graft versus host disease. The toxins
CC   can also be used to selectively kill unwanted cells in culture. The new
CC   ribonucleases have increased cytotoxic activity compared to nOnc and
CC   also lower immunogenicity in humans.
XX
SQ   Sequence   355 AA;

  Query Match             46.5%;  Score 281.5;  DB 18;  Length 355;
  Best Local Similarity   50.0%;  Pred. No. 6.4e-24;
  Matches   56;  Conservative   15;  Mismatches   32;  Indels    9;  Gaps    4;

Qy          1 MSNWATFQQKHIINT-PIICNTIMDNNIYIVGGQCKRVNTFIISSATTVKAICTGVI-NM 58
              ||:| |||:||| ||  : |: ||  |::     ||  |||| |    ||||| |:| :
Db        251 MSDWLTFQKKHITNTRDVDCDNIMSTNLF----HCKDKNTFIYSRPEPVKAICKGIIASK 306

Qy         59 NVLSTTRFQLNTCTRTSITPRPCPYSSRTETNYICVKCENQYPVHFAGIGRC 110
              |||:|: | |: |   ::| ||| |  :  ||  || |||| |||| |:| |
Db        307 NVLTTSEFYLSDC---NVTSRPCKYKLKKSTNKFCVTCENQAPVHFVGVGSC 355


RESULT 15
AAW35133
ID   AAW35133 standard; Protein; 355 AA.
XX
AC   AAW35133;
XX
DT   20-APR-1998  (first entry)
XX
DE   R. pipiens recombinant RNase rOnc fusion protein 9.
XX
KW   RNase A; ribonuclease; cytotoxic; onconase; nOnc; immunofusion;
KW   tumour cell growth; frog.
XX
OS   Rana pipiens.
OS   Synthetic.
XX
PN   WO9731116-A2.
XX
PD   28-AUG-1997.
XX
PF   19-FEB-1997;   97WO-US02588.
XX
PR   21-FEB-1996;   96US-0011800.
XX
PA   (USSH ) US DEPT HEALTH & HUMAN SERVICES.
XX
PI   Boque L,  Newton DL,  Rybak SM,  Wlodawer A;
XX
DR   WPI; 1997-435168/40.
DR   N-PSDB; AAT94971.
XX
PT   Ribonuclease molecules based on native Onconase - used for killing
PT   cells, particularly tumour cells
XX
PS   Disclosure; Page 75; 90pp; English.
XX
CC   Sequences AAW35125 to AAW35135 represent recombinant fusion proteins
CC   (rOnc) which are modifications of the RNase Onconase (RTM) (nOnc). Such
CC   novel ribonuclease molecules are highly cytotoxic and can be used alone
CC   or to form chemical conjugates or to target recombinant immunofusions.
CC   They are used particularly for decreasing tumour cell growth. They can
CC   also be used for cell separation in vitro by selectively killing unwanted
CC   types of cells, e.g. in bone marrow prior to transplantation into a
CC   patient undergoing marrow ablation by radiation, or for killing leukaemia
CC   cells or T-cells that would cause graft versus host disease. The toxins
CC   can also be used to selectively kill unwanted cells in culture. The new
CC   ribonucleases have increased cytotoxic activity compared to nOnc and
CC   also lower immunogenicity in humans.
XX
SQ   Sequence   355 AA;

  Query Match             46.5%;  Score 281.5;  DB 18;  Length 355;
  Best Local Similarity   50.0%;  Pred. No. 6.4e-24;
  Matches   56;  Conservative   15;  Mismatches   32;  Indels    9;  Gaps    4;

Qy          1 MSNWATFQQKHIINT-PIICNTIMDNNIYIVGGQCKRVNTFIISSATTVKAICTGVI-NM 58
              ||:| |||:||| ||  : |: ||  |::     ||  |||| |    ||||| |:| :
Db          1 MSDWLTFQKKHITNTRDVDCDNIMSTNLF----HCKDKNTFIYSRPEPVKAICKGIIASK 56

Qy         59 NVLSTTRFQLNTCTRTSITPRPCPYSSRTETNYICVKCENQYPVHFAGIGRC 110
              |||:|: | |: |   ::| ||| |  :  ||  || |||| |||| |:| |
Db         57 NVLTTSEFYLSDC---NVTSRPCKYKLKKSTNKFCVTCENQAPVHFVGVGSC 105


Search completed: June 25, 2003, 14:48:42
Job time : 34.3 secs
```